These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 10022687)

  • 1. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
    Crew JP; O'Brien T; Bicknell R; Fuggle S; Cranston D; Harris AL
    J Urol; 1999 Mar; 161(3):799-804. PubMed ID: 10022687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.
    Crew JP; O'Brien T; Bradburn M; Fuggle S; Bicknell R; Cranston D; Harris AL
    Cancer Res; 1997 Dec; 57(23):5281-5. PubMed ID: 9393750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of vascular endothelial growth factor in primary superficial bladder cancer.
    Chow NH; Liu HS; Chan SH; Cheng HL; Tzai TS
    Anticancer Res; 1999; 19(5C):4593-7. PubMed ID: 10650816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression.
    Crew JP; Fuggle S; Bicknell R; Cranston DW; de Benedetti A; Harris AL
    Br J Cancer; 2000 Jan; 82(1):161-6. PubMed ID: 10638984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
    Bok RA; Halabi S; Fei DT; Rodriquez CR; Hayes DF; Vogelzang NJ; Kantoff P; Shuman MA; Small EJ
    Cancer Res; 2001 Mar; 61(6):2533-6. PubMed ID: 11289126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of VEGF and tumor angiogenesis in bladder cancer].
    Wang S; Xia T; Zhang Z; Kong X; Zeng L; Mi P; Xue Z
    Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):34-6. PubMed ID: 11831983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
    Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
    Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.
    Fine BA; Valente PT; Feinstein GI; Dey T
    Gynecol Oncol; 2000 Jan; 76(1):33-9. PubMed ID: 10620438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival.
    Chen CA; Cheng WF; Lee CN; Wei LH; Chu JS; Hsieh FJ; Hsieh CY
    Gynecol Oncol; 2001 Feb; 80(2):207-12. PubMed ID: 11161861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
    Hazelton D; Nicosia RF; Nicosia SV
    Clin Cancer Res; 1999 Apr; 5(4):823-9. PubMed ID: 10213218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
    Tabone MD; Landman-Parker J; Arcil B; Coudert MC; Gerota I; Benbunan M; Leverger G; Dosquet C
    Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
    Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
    Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
    Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
    J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer.
    Xia G; Kumar SR; Hawes D; Cai J; Hassanieh L; Groshen S; Zhu S; Masood R; Quinn DI; Broek D; Stein JP; Gill PS
    J Urol; 2006 Apr; 175(4):1245-52. PubMed ID: 16515971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
    Bian W; Xu Z
    Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer.
    Bernardini S; Fauconnet S; Chabannes E; Henry PC; Adessi G; Bittard H
    J Urol; 2001 Oct; 166(4):1275-9. PubMed ID: 11547057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors.
    Jeon SH; Lee SJ; Chang SG
    Oncol Rep; 2001; 8(6):1265-7. PubMed ID: 11605046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.
    Poon RT; Lau CP; Cheung ST; Yu WC; Fan ST
    Cancer Res; 2003 Jun; 63(12):3121-6. PubMed ID: 12810638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
    Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer.
    Aoki S; Yamada Y; Nakamura K; Taki T; Tobiume M; Honda N
    Oncol Rep; 2006 Aug; 16(2):279-84. PubMed ID: 16820903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.